2018 American Transplant Congress
Proton Pump Inhibitor Use among Kidney Transplant Recipients
Vanderbilt University Medical Center, Nashville, TN.
Background: Proton Pump Inhibitors (PPIs) have been associated with CKD and other serious adverse effects. PPI use in the transplant population has not been well-described.…2018 American Transplant Congress
Haematological Autoimmune Disorders Associated with Alemtuzumab Induction in Renal and Simultaneous Pancreas and Kidney Recipients
Introduction Haematological Autoimmune Disorders (HAD) have been associated with Alemtuzumab (Az); namely immune thrombocytopenia (ITP), autoimmune haemolytic anaemia (AIHA), Evans syndrome (ES) and Red Cell…2018 American Transplant Congress
Safety and Efficacy of Sofosbuvir-Based Direct-Acting Antiviral Agents in Kidney Transplant Recipients with HCV: A Systematic Review and Meta-Analysis
Background: Outcome data on sofosbuvir (SOF)-based therapy in patients with kidney transplantation (KTx) with hepatitis C virus infection are limited with individual studies having a…2017 American Transplant Congress
De Novo Low-Dose Sirolimus versus Mycophenolate Mofetil in Combination with Extended-Release Tacrolimus in Kidney Transplant Recipients.
Previous studies reported that tacrolimus (TAC) with high-dose sirolimus (SRL) was associated with worse outcomes in kidney transplantation, compared to TAC with mycophenolate mofetil (MMF.).…2017 American Transplant Congress
Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation.
Low tacrolimus (FK) trough concentrations have been associated with higher risk of acute rejection, particularly within African-American (AA) kidney transplant recipients; less is known about…2017 American Transplant Congress
Applicability and Safety of a Regulatory T Cell Therapy in Adult Liver Transplantation: The “ThRIL” Phase I First-in-Human Trial.
MRC Centre for Transplantation, King's College London, London, United Kingdom
Aim“ThRIL” is a multiple site, open-label, uncontrolled, phase I clinical trial assessing the safety and applicability of a CD4+CD25+FOXP3+ regulatory T cell (Treg) immunotherapy in…2017 American Transplant Congress
Dementia and Alzheimer's Disease Among Older Kidney Transplant Recipients.
Background: Kidney transplantation (KT) is a growing treatment option for older ESRD patients. Older recipients may develop post-KT dementia and Alzheimer's disease (AD) associated with…2017 American Transplant Congress
Impact of Donor Asystole in Intestine Transplant.
Surgery, Indiana University, Indianapolis, IN
Intestine transplantation has a high risk of post-transplant complications. For this reason, many intestine transplant centers are conservative in their choice of deceased donors, using…2017 American Transplant Congress
Single-Center Initial Experience in Treating Chronic Hepatitis C in Kidney Transplant Recipients.
Nephrology and Kidney Transplant Department, ISCMPA, Porto Alegre, RS, Brazil
Chronic hepatitis C (HCV) infection is a prevalent condition in end-stage renal disease and presents an important clinical challenge in kidney transplant recipients (KTR). Interferon-based…2017 American Transplant Congress
Alemtuzumab Induction Is Safe, and Permits the Avoidance of Steroids in the Majority of Renal Transplant Recipients.
IntroductionThe introduction of alemtuzumab into routine clinical use has been hindered by safety concerns surrounding its prolonged effect on the lymphoid compartment. Here we report…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 18
- Next Page »